Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Spero Therapeutics Inc (NASDAQ:SPRO)

14.49
Delayed Data
As of Nov 17
 0.00 / 0.00%
Today’s Change
10.83
Today|||52-Week Range
15.40
--
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$194.1M

Company Description

Spero Therapeutics, Inc. develops novel therapies for the treatment of resistant bacterial infections. It engages in the research and development of mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterial infections. The company's program addresses an unusual target driving virulence and persistence of pseudomonas aeruginosa infections and other gram-negative pathogens. Spero Therapeutics was founded by Ankit Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Contact Information

Spero Therapeutics, Inc.
675 Massachusetts Avenue
Cambridge Massachusetts 02139
P:(857) 242-1600
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Ankit A. MahadeviaPresident, Chief Executive Officer & Director
Cristina LarkinChief Operating Officer
Joel D. SendekChief Financial Officer
Thomas R. ParrChief Scientific Officer
Timothy KeutzerSenior Vice President-Development